Logo image of ANIP

ANI PHARMACEUTICALS INC (ANIP) Stock Fundamental Analysis

NASDAQ:ANIP - Nasdaq - US00182C1036 - Common Stock - Currency: USD

57.27  -1.81 (-3.06%)

After market: 57.27 0 (0%)

Fundamental Rating

5

Taking everything into account, ANIP scores 5 out of 10 in our fundamental rating. ANIP was compared to 198 industry peers in the Pharmaceuticals industry. ANIP has an average financial health and profitability rating. An interesting combination arises when we look at growth and value: ANIP is growing strongly while it also seems undervalued.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year ANIP was profitable.
In the past year ANIP had a positive cash flow from operations.
ANIP had negative earnings in 4 of the past 5 years.
Of the past 5 years ANIP 4 years had a positive operating cash flow.
ANIP Yearly Net Income VS EBIT VS OCF VS FCFANIP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

1.2 Ratios

ANIP has a Return On Assets of -0.50%. This is amongst the best in the industry. ANIP outperforms 80.81% of its industry peers.
The Return On Equity of ANIP (-1.45%) is better than 82.32% of its industry peers.
ANIP has a Return On Invested Capital of 2.10%. This is in the better half of the industry: ANIP outperforms 78.28% of its industry peers.
Industry RankSector Rank
ROA -0.5%
ROE -1.45%
ROIC 2.1%
ROA(3y)-2.12%
ROA(5y)-3.36%
ROE(3y)-5.31%
ROE(5y)-7.87%
ROIC(3y)N/A
ROIC(5y)N/A
ANIP Yearly ROA, ROE, ROICANIP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10 -10

1.3 Margins

ANIP's Operating Margin of 3.58% is fine compared to the rest of the industry. ANIP outperforms 79.29% of its industry peers.
In the last couple of years the Operating Margin of ANIP has declined.
ANIP has a better Gross Margin (60.17%) than 68.18% of its industry peers.
In the last couple of years the Gross Margin of ANIP has declined.
Industry RankSector Rank
OM 3.58%
PM (TTM) N/A
GM 60.17%
OM growth 3YN/A
OM growth 5Y-47.18%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.51%
GM growth 5Y-3.12%
ANIP Yearly Profit, Operating, Gross MarginsANIP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

4

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ANIP is destroying value.
Compared to 1 year ago, ANIP has more shares outstanding
The number of shares outstanding for ANIP has been increased compared to 5 years ago.
The debt/assets ratio for ANIP is higher compared to a year ago.
ANIP Yearly Shares OutstandingANIP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
ANIP Yearly Total Debt VS Total AssetsANIP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

ANIP has an Altman-Z score of 1.82. This is not the best score and indicates that ANIP is in the grey zone with still only limited risk for bankruptcy at the moment.
ANIP has a better Altman-Z score (1.82) than 68.18% of its industry peers.
ANIP has a debt to FCF ratio of 9.35. This is a negative value and a sign of low solvency as ANIP would need 9.35 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 9.35, ANIP belongs to the top of the industry, outperforming 80.30% of the companies in the same industry.
A Debt/Equity ratio of 1.38 is on the high side and indicates that ANIP has dependencies on debt financing.
The Debt to Equity ratio of ANIP (1.38) is worse than 73.74% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.38
Debt/FCF 9.35
Altman-Z 1.82
ROIC/WACC0.22
WACC9.57%
ANIP Yearly LT Debt VS Equity VS FCFANIP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 2.66 indicates that ANIP has no problem at all paying its short term obligations.
ANIP has a Current ratio of 2.66. This is comparable to the rest of the industry: ANIP outperforms 49.49% of its industry peers.
ANIP has a Quick Ratio of 1.98. This is a normal value and indicates that ANIP is financially healthy and should not expect problems in meeting its short term obligations.
ANIP has a Quick ratio of 1.98. This is comparable to the rest of the industry: ANIP outperforms 45.96% of its industry peers.
Industry RankSector Rank
Current Ratio 2.66
Quick Ratio 1.98
ANIP Yearly Current Assets VS Current LiabilitesANIP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

7

3. Growth

3.1 Past

ANIP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.54%, which is quite good.
The Earnings Per Share has been growing slightly by 0.59% on average over the past years.
The Revenue has grown by 56.85% in the past year. This is a very strong growth!
ANIP shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.37% yearly.
EPS 1Y (TTM)19.54%
EPS 3Y16.84%
EPS 5Y0.59%
EPS Q2Q%40.5%
Revenue 1Y (TTM)56.85%
Revenue growth 3Y41.66%
Revenue growth 5Y24.37%
Sales Q2Q%43.43%

3.2 Future

Based on estimates for the next years, ANIP will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.43% on average per year.
Based on estimates for the next years, ANIP will show a quite strong growth in Revenue. The Revenue will grow by 9.67% on average per year.
EPS Next Y26.64%
EPS Next 2Y17.87%
EPS Next 3Y16.98%
EPS Next 5Y12.43%
Revenue Next Year30.55%
Revenue Next 2Y18.48%
Revenue Next 3Y14.28%
Revenue Next 5Y9.67%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ANIP Yearly Revenue VS EstimatesANIP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
ANIP Yearly EPS VS EstimatesANIP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2 4 6 8 10

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

ANIP is valuated reasonably with a Price/Earnings ratio of 10.07.
Compared to the rest of the industry, the Price/Earnings ratio of ANIP indicates a rather cheap valuation: ANIP is cheaper than 89.90% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 25.91. ANIP is valued rather cheaply when compared to this.
The Price/Forward Earnings ratio is 7.93, which indicates a rather cheap valuation of ANIP.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ANIP indicates a rather cheap valuation: ANIP is cheaper than 87.37% of the companies listed in the same industry.
ANIP is valuated cheaply when we compare the Price/Forward Earnings ratio to 21.85, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 10.07
Fwd PE 7.93
ANIP Price Earnings VS Forward Price EarningsANIP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ANIP is valued cheaper than 80.30% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ANIP indicates a rather cheap valuation: ANIP is cheaper than 83.33% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 18.55
EV/EBITDA 16.54
ANIP Per share dataANIP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ANIP's earnings are expected to grow with 16.98% in the coming years.
PEG (NY)0.38
PEG (5Y)17.14
EPS Next 2Y17.87%
EPS Next 3Y16.98%

More info and screens

0

5. Dividend

5.1 Amount

ANIP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANI PHARMACEUTICALS INC

NASDAQ:ANIP (5/22/2025, 8:00:00 PM)

After market: 57.27 0 (0%)

57.27

-1.81 (-3.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-09 2025-05-09/bmo
Earnings (Next)08-04 2025-08-04/bmo
Inst Owners95.29%
Inst Owner Change3.54%
Ins Owners6.75%
Ins Owner Change7.3%
Market Cap1.24B
Analysts84.29
Price Target83.06 (45.03%)
Short Float %11.11%
Short Ratio4.79
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP-25.25%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.96%
Min EPS beat(2)11.36%
Max EPS beat(2)20.55%
EPS beat(4)4
Avg EPS beat(4)14.54%
Min EPS beat(4)5.26%
Max EPS beat(4)20.97%
EPS beat(8)8
Avg EPS beat(8)28.1%
EPS beat(12)11
Avg EPS beat(12)36.05%
EPS beat(16)12
Avg EPS beat(16)13.46%
Revenue beat(2)2
Avg Revenue beat(2)6.75%
Min Revenue beat(2)6.54%
Max Revenue beat(2)6.96%
Revenue beat(4)4
Avg Revenue beat(4)4.78%
Min Revenue beat(4)0.74%
Max Revenue beat(4)6.96%
Revenue beat(8)8
Avg Revenue beat(8)7.86%
Revenue beat(12)12
Avg Revenue beat(12)8.42%
Revenue beat(16)14
Avg Revenue beat(16)6.64%
PT rev (1m)0.53%
PT rev (3m)7.71%
EPS NQ rev (1m)-5.48%
EPS NQ rev (3m)9.33%
EPS NY rev (1m)2.14%
EPS NY rev (3m)16.15%
Revenue NQ rev (1m)-0.26%
Revenue NQ rev (3m)5.9%
Revenue NY rev (1m)1.76%
Revenue NY rev (3m)7.94%
Valuation
Industry RankSector Rank
PE 10.07
Fwd PE 7.93
P/S 1.52
P/FCF 18.55
P/OCF 15.3
P/B 2.79
P/tB N/A
EV/EBITDA 16.54
EPS(TTM)5.69
EY9.94%
EPS(NY)7.22
Fwd EY12.61%
FCF(TTM)3.09
FCFY5.39%
OCF(TTM)3.74
OCFY6.54%
SpS37.62
BVpS20.56
TBVpS-7.22
PEG (NY)0.38
PEG (5Y)17.14
Profitability
Industry RankSector Rank
ROA -0.5%
ROE -1.45%
ROCE 2.66%
ROIC 2.1%
ROICexc 2.45%
ROICexgc 6.82%
OM 3.58%
PM (TTM) N/A
GM 60.17%
FCFM 8.21%
ROA(3y)-2.12%
ROA(5y)-3.36%
ROE(3y)-5.31%
ROE(5y)-7.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-44.22%
ROICexc growth 3YN/A
ROICexc growth 5Y-46.62%
OM growth 3YN/A
OM growth 5Y-47.18%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.51%
GM growth 5Y-3.12%
F-Score4
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 1.38
Debt/FCF 9.35
Debt/EBITDA 5.83
Cap/Depr 18.61%
Cap/Sales 1.74%
Interest Coverage 1.15
Cash Conversion 76.92%
Profit Quality N/A
Current Ratio 2.66
Quick Ratio 1.98
Altman-Z 1.82
F-Score4
WACC9.57%
ROIC/WACC0.22
Cap/Depr(3y)17.9%
Cap/Depr(5y)14.57%
Cap/Sales(3y)2.42%
Cap/Sales(5y)2.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.54%
EPS 3Y16.84%
EPS 5Y0.59%
EPS Q2Q%40.5%
EPS Next Y26.64%
EPS Next 2Y17.87%
EPS Next 3Y16.98%
EPS Next 5Y12.43%
Revenue 1Y (TTM)56.85%
Revenue growth 3Y41.66%
Revenue growth 5Y24.37%
Sales Q2Q%43.43%
Revenue Next Year30.55%
Revenue Next 2Y18.48%
Revenue Next 3Y14.28%
Revenue Next 5Y9.67%
EBIT growth 1Y-44.16%
EBIT growth 3YN/A
EBIT growth 5Y-34.31%
EBIT Next Year29.93%
EBIT Next 3Y18.6%
EBIT Next 5Y13.48%
FCF growth 1Y55608.3%
FCF growth 3Y297.63%
FCF growth 5Y4.15%
OCF growth 1Y781.43%
OCF growth 3Y168.16%
OCF growth 5Y7.01%